EYEG - EyeGate Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.1783
-0.0126 (-6.60%)
As of 2:42PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.1965
Open0.1965
Bid0.1783 x 900
Ask0.1790 x 1200
Day's Range0.1500 - 0.1915
52 Week Range0.1500 - 0.6400
Volume383,227
Avg. Volume493,918
Market Cap8.144M
Beta (3Y Monthly)1.96
PE Ratio (TTM)N/A
EPS (TTM)-0.1520
Earnings DateMar 1, 2019 - Mar 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • ACCESSWIRE

    EyeGate Pharma Reports Second Quarter 2019 Financial Results and Provides Business Update

    WALTHAM, MA / ACCESSWIRE / August 8, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today announced financial results for the quarter ended June 30, 2019 and provided an update on recent corporate and operational activities. Stephen From, Chief Executive Officer of EyeGate, said, “I am pleased with the clinical progress of our lead product, the Ocular Bandage Gel (“OBG”). In addition, we expect the follow-on PE pilot study to be underway in the near future.

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For August 5, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Allakos (NASDAQ: ALLK ) shares were up 112.6% ...

  • Benzinga

    Eyegate Pharmaceuticals Receives FDA Approval To Begin PE Pilot Study

    Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG) shares are trading higher after the company received FDA approval to initiate its follow-on pilot study for punctate epitheliopathies (PE). The study will use the Ocular Bandage Gel eye drop to treat patients with PE, which can be associated with dry eyes. "We are excited to get underway with another clinical study and very pleased with our continued cooperation and collaboration with the FDA," said CEO Stephen From.

  • ACCESSWIRE

    EyeGate Pharma Receives Approval from FDA to Initiate PE Pilot Study

    WALTHAM, MA / ACCESSWIRE / August 5, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has received approval from the U.S. Food and Drug Administration (“FDA”) to initiate its follow-on pilot study for punctate epitheliopathies (“PE”). The study will use the Ocular Bandage Gel (“OBG”) eye drop to treat patients with PE, which can be associated with dry eye.

  • ACCESSWIRE

    EyeGate Pharma Announces Randomization of First 25% of Patients in Pivotal Study

    WALTHAM, MA / ACCESSWIRE / July 31, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has completed randomization of over 25% of the patients required for its corneal wound repair pivotal study using the Ocular Bandage Gel (“OBG”) eye drop. The pivotal study will enroll and randomize up to 270 patients requiring corneal wound repair following photorefractive keratectomy (“PRK”) surgery.

  • ACCESSWIRE

    EyeGate Files FDA Submission to Initiate PE Pilot Study

    WALTHAM, MA / ACCESSWIRE / July 9, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today it has filed a protocol with the FDA for a follow-on pilot study using the Ocular Bandage Gel ("OBG") eye drop to treat punctate epitheliopathies ("PE") which can be associated with dry eye. The FDA review process takes 30 days, at which point the FDA will allow the Company to initiate enrollment or will provide comments to be addressed. The objective of this study is to evaluate several different exploratory performance endpoints in PE patients.

  • ACCESSWIRE

    EyeGate Announces First Patient Enrolled in PRK Pivotal Study

    WALTHAM, MA / ACCESSWIRE / June 26, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or "the Company") announced today it has enrolled the first patient in its corneal wound repair pivotal study in patients having undergone photorefractive keratectomy ("PRK") surgery. Barbara Wirostko MD, Chief Medical Officer of EyeGate, said, "There is a significant need for an effective and accessible Hyaluronic Acid ("HA") eyedrop formulation in the U.S. that can help re-epithelialize corneal defects due to surgery, injuries, and diseases.

  • Zacks Small Cap Research

    EYEG: FDA Approves IDE. We Like Chances of Success of Upcoming OBG-PRK Pivotal Study

    By Brian Marckx, CFA NASDAQ:EYEG READ THE FULL EYEG RESEARCH REPORT FDA Approves IDE for OBG-PRK Pivotal Study, Topline Results Expected Later This Year… The major recent news on the operating front was ...

  • ACCESSWIRE

    EyeGate Receives Approval from FDA to Initiate PRK Pivotal Study

    WALTHAM, MA / ACCESSWIRE / June 3, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or "the Company") announced today it has received approval from the U.S. Food and Drug Administration ("FDA") to initiate its photorefractive keratectomy ("PRK") pivotal study. The FDA has determined that EyeGate provided sufficient data to support initiation of the clinical study and has requested that EyeGate make some modifications to the patient informed consent document prior to enrollment. Stephen From, CEO of EyeGate, said, "We are extremely pleased with the feedback received from the FDA regarding the design of our PRK pivotal study and plan to begin enrollment as soon as possible.

  • ACCESSWIRE

    EyeGate Pharma Receives Positive Nasdaq Listing Determination

    WALTHAM, MA / ACCESSWIRE / May 14, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or "the Company") today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for the continued listing of its securities on The Nasdaq Capital Market ("Nasdaq"). The Company's continued listing on Nasdaq is subject to the Company evidencing a closing bid price of at least $1.00 per share for a minimum of ten consecutive trading days on or before September 16, 2019, which period constitutes the full extent of the Panel's discretion in this matter. EyeGate's OBG platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid ("CMHA-S"), a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface.

  • ACCESSWIRE

    EyeGate Pharma Reports First Quarter 2019 Financial Results and Provides Business Update

    WALTHAM, MA / ACCESSWIRE / May 8, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or "the Company") today announced financial results for the quarter ended March 31, 2019 and provided an update on recent corporate and operational activities. Stephen From, EyeGate's Chief Executive Officer, said, "During the first quarter of 2019, we continued to execute on our strategic initiatives, successfully confirming our path to a de novo filing for our lead product, Ocular Bandage Gel ("OBG"). Meeting held with the U.S. Food and Drug Administration ("FDA") on March 20, 2019 confirming the Company's path to a de novo filing for its OBG product for the indication of PRK surgery.

  • Zacks Small Cap Research

    EYEG: EYEG Submits IDE to FDA Seeking Approval to Commence Pivotal PRK Study

    This morning EyeGate (EYEG) announced that they submitted an Investigational Device Exemption (IDE) application to the FDA seeking approval to commence a pivotal study for OBG in PRK. FDA turnaround is anticipated in approximately 30 days. EYEG notes that while they wait for the U.S. regulatory agency’s answer, they will continue with the initiation of the planned study which, if successful, is expected to be used as primary support for a De Novo filing.

  • ACCESSWIRE

    EyeGate Files IDE with FDA for PRK Pivotal Study

    WALTHAM, MA / ACCESSWIRE / May 2, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) (''EyeGate'' or ''the Company'') announced today it has successfully submitted the Investigational Device Exemption (''IDE'') to the U.S. Food and Drug Administration (''FDA") regarding its photorefractive keratectomy (''PRK'') pivotal study. The review process takes 30 days, at which point the FDA will allow the Company to initiate enrollment or will provide comments to be addressed. Stephen From, CEO of EyeGate, said, ''Following the strength of our data in the PRK pilot study, the FDA recommended that we are ready to commence a pivotal study, which if successful, will allow us to file a de novo submission.

  • Zacks Small Cap Research

    EYEG: Our Take On EYEG Moving Towards OBG-PRK Pivotal Study

    EyeGate (EYEG) announced financial results for their fourth quarter ending December 31st. For the full year, revenue was $1.7M, all of which relates to recognition of milestones from the EGP-437 development agreements with Bausch Health Companies (BHC). In the 10-K, EYEG discloses that they received a notice of termination from BHC on December 14th notifying them that BHC is voluntarily terminating these agreements effective March 14, 2019.

  • ACCESSWIRE

    EyeGate Confirms Path to De Novo Filing with FDA

    WALTHAM, MA / ACCESSWIRE / March 26, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or "the Company") has met with the U.S. Food and Drug Administration ("FDA") regarding its Ocular Bandage Gel ("OBG") product and has confirmed its path to a de novo filing. The FDA has agreed that based on the strength of data from the photorefractive keratectomy ("PRK") pilot study, EyeGate is ready to move forward with a pivotal study, which will allow for a de novo filing. The Company plans to file the Investigational Device Exemption ("IDE") for initiation of the study in Q2 2019 and to complete the study in Q3 2019 with the de novo being filed soon thereafter.

  • ACCESSWIRE

    EyeGate Pharmaceuticals Reports Full Year 2018 Financial Results and Provides Business Update

    WALTHAM, MA / ACCESSWIRE / March 1, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) (''EyeGate'' or ''the Company'') today announced financial results for the year ended December 31, 2018 and provided an update on recent corporate and operational activities. Stephen From, EyeGate's Chief Executive Officer, said, ''This year EyeGate reached critical turning points in the path toward regulatory filings for approval and commercialization enabling us to further execute our strategy moving into 2019. Mr. From continued, ''We also reported positive topline data in key OBG clinical studies for both indications, photorefractive keratectomy (''PRK'') surgery and punctate epitheliopathies (''PE'').

  • GlobeNewswire

    EyeGate Pharmaceuticals to Present at BIO CEO & Investor Conference in New York City

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”) today announced that the Company will attend and present at the 21st BIO CEO & Investor Conference being held in New York, NY at the New York Marriott Marquis on February 11th & 12th, 2019. The Company will also host one-on-one meetings through BIO CEO & Investor conference, which is one of the largest, unbiased forums of institutional investors, industry analysts, and biotechnology executives. Conference attendees can request meetings through the One-on-One Partnering platform, while non-attendees can send meeting requests to Joe Green at Edison Advisors.

  • GlobeNewswire

    EyeGate Pharmaceuticals Announces Meeting Date with FDA

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”) today confirmed that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on Wednesday, March 20th, 2019 to discuss EyeGate’s de novo application strategy for its Ocular Bandage Gel (OBG) product, which will cover the clinical plan, data to date, and potential submission timelines. EyeGate’s OBG platform, a unique cross-linked hyaluronic acid compound, has potentially broad applications in managing ocular surface damage due to a variety of conditions, ranging from punctate epitheliopathies (PE) commonly found in dry eye patients, to large epithelial defects like those that occur following photorefractive keratectomy (PRK). EyeGate’s OBG platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S), a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface.

  • Zacks Small Cap Research

    EYEG: Is EyeGate Eyeing FDA Filings Following Positive OBG Data in Both PRK and PE?

    EyeGate (EYEG) announced Q3 financial results and provided a business update. To-date, EYEG has received $13.8M in upfront and milestones under the two agreements, including ~$300k in the most recent quarter. While the yoy decrease reflects a change in activity from the relatively large EGP-437 trials to the smaller OBG studies, the qoq increase is a result of continued progression of both OBG programs.

  • GlobeNewswire

    Investor Expectations to Drive Momentum within Atomera, YogaWorks, Cellect Biotechnology, Eyegate Pharmaceuticals, Zealand Pharma A/S, and Polar Power — Discovering Underlying Factors of Influence

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRE

    Drug Sales Up, Biotech Stocks Down, Here's a Profit Opportunity

    HENDERSON, NV / ACCESSWIRE / November 14, 2018 / With the sharp declines in biotechnology stocks, with the iShares Nasdaq Biotechnology exchange traded fund (ETF) and SPDR S&P Biotech ETF recently down ...

  • ACCESSWIRE

    Today’s Research Reports on Stocks to Watch: Viking Therapeutics and EyeGate Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / November 14, 2018 / Shares of EyeGate exploded on Tuesday on tremendous volume after reporting third quarter financial results. Shares of Viking Therapeutics were little changed ...

  • GlobeNewswire

    EyeGate Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”) today announced financial results for the three-month period ended September 30, 2018 and provided an update on recent corporate and operational activities. Stephen From, EyeGate’s Chief Executive Officer, said, “The third quarter of 2018 was a transformative quarter for EyeGate, with the Company receiving FDA approval for two IDE submissions for our Ocular Bandage Gel ('OBG') product, as well as focusing our efforts toward the key clinical trials that support this innovative product.” Mr. From continued, “We are extremely pleased to have announced positive top-line data in each of our OBG studies for photorefractive keratectomy ('PRK') surgery and punctate epitheliopathies ('PE').

  • ACCESSWIRE

    4 Healthcare Stocks Investors Are Watching In November

    Eighty-three percent of healthcare organizations responding to an American Telemedicine Association* poll said they are highly likely to invest in telehealth with operational efficiency and convenience in mind. Of the 171 healthcare executives participating in the annual ATA Executive Leadership Survey, 88% of those who are likely to purchase telehealth tools are planning to do so. "This executive leadership survey confirms undeniably today's leaders view telemedicine as a major driver in transforming healthcare," said Jonathan Linkous, CEO, American Telemedicine Association.

  • GlobeNewswire

    EyeGate Pharma Announces Positive Results in Punctate Epitheliopathy Study

    EyeGate Pharmaceuticals, Inc. (EYEG) today announced top-line data from its study evaluating the potential of EyeGate’s Ocular Bandage Gel (OBG) to help clinicians better manage patients with punctate epitheliopathies (PE) due to pathologies such as dry eye. Randall J Olson, M.D., CEO and Chair of the Department of Ophthalmology and Visual Sciences of the John A. Moran Eye Center, University of Utah, SLC, said, “A product that achieves symptomology results as seen in this study is exactly what ophthalmologists want access to when treating patients. This controlled, masked study enrolled 30 subjects with punctate epitheliopathies (PE) due to pathologies such as dry eye.